Pfizer and Flynn Pharma fined £69 million for charging excessive prices on epilepsy drugs
Pfizer and Flynn Pharma, manufacturers of phenytoin sodium capsules which are used to treat epilepsy, have been fined a combined total of £69 million by the Competitions Appeal Tribunal (CAT) for “charging excessive prices” between 2012 and 2016. Around 48,000 people with epilepsy in the UK depend on the drugs supplied by Flynn Pharma and …